Market capitalization | $2.19m |
Enterprise Value | $-760.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.14 |
P/B ratio (TTM) P/B ratio | 0.75 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-5.22m |
Free Cash Flow (TTM) Free Cash Flow | $-5.29m |
Cash position | $3.28m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -5.21 -5.21 |
72%
72%
|
EBIT (Operating Income) EBIT | -5.22 -5.22 |
72%
72%
|
Net Profit | -4.99 -4.99 |
72%
72%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius' clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.
Head office | United States |
CEO | David Arthur |
Employees | 2 |
Founded | 2014 |
Website | salariuspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.